Last reviewed · How we verify
GW642444
GW642444 is a long-acting beta-2 adrenergic receptor agonist that stimulates bronchial smooth muscle relaxation to improve airflow in respiratory disease.
GW642444 is a long-acting beta-2 adrenergic receptor agonist that stimulates bronchial smooth muscle relaxation to improve airflow in respiratory disease. Used for Chronic obstructive pulmonary disease (COPD), Asthma (maintenance therapy).
At a glance
| Generic name | GW642444 |
|---|---|
| Also known as | Placebo, vilanterol trifenatate, GSK233705 |
| Sponsor | GlaxoSmithKline |
| Drug class | Long-acting beta-2 agonist (LABA) |
| Target | Beta-2 adrenergic receptor (ADRB2) |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | Phase 3 |
Mechanism of action
As a beta-2 agonist, GW642444 binds to beta-2 adrenergic receptors on airway smooth muscle, triggering intracellular signaling that leads to muscle relaxation and bronchodilation. The long-acting formulation provides sustained therapeutic effect over extended dosing intervals, making it suitable for maintenance therapy in chronic respiratory conditions.
Approved indications
- Chronic obstructive pulmonary disease (COPD)
- Asthma (maintenance therapy)
Common side effects
- Tremor
- Headache
- Palpitations
- Nervousness
Key clinical trials
- A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma (PHASE3)
- Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma (PHASE3)
- Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD (PHASE2)
- An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Asthma (PHASE3)
- A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma (PHASE3)
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
- A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD (PHASE3)
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GW642444 CI brief — competitive landscape report
- GW642444 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI